Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$56.66 USD
-2.41 (-4.08%)
Updated Aug 2, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Earnings News For CRBP
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
-
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?